Serglycin level in peripheral circulating blood cells has prognostic significance in patients with hepatocellular carcinoma
- Oxford University Press (OUP)
- Publication Type:
- Conference Proceeding
- Annals of Oncology, 2019
- Issue Date:
|P-030Serglycin level in peripheral circulating blood cells has prognostic significance in patients with hepatocellular carcinoma _ Annals of Oncology _ Oxford Academic.pdf||Published version||150.75 kB|
Copyright Clearance Process
- Recently Added
- In Progress
- Closed Access
This item is closed access and not available.
Background: Many inflammation markers in peripheral blood cells, which act as prognostic factors for the survival of hepatocellular carcinoma (HCC), are limited by active infection. Serglycin is a major proteoglycan in blood cells associated with inflammation and malignancy. The present study investigated if serglycin could be used as a prognosis marker of survival of HCC without the influence of infection. Methods: From May, 2013 to May, 2015, 130 hepatitis B virus (HBV) induced HCC patients were enrolled in the study. The patients were divided into group 1 (without infection), and group 2 (with infection), with 30 healthy adults enrolled as the control group. Clinical patient data were collected before treatment with transarterial chemoembolization (TACE). The expression of serglycin in peripheral blood cells was examined by flow cytometry. Receiver operating characteristic curve (ROC) curve analysis was performed to select the cut-off values for serglycin and other indicators to stratify patients. The Cox model and Kaplan-Meier analyses were performed to identify the predictors for overall survival (OS). Results: The serglycin levels in peripheral blood cells were significantly higher in both the HCC groups than those in the control group. OS was studied in group 1 because many inflammation markers were limited to patients with infection. Cholinesterase (CHE <4300 U/L), lung metastasis, average fluorescence intensity of serglycin in neutrophils (N1>47.4%), and the aspartate aminotransferase (AST)-to-platelet ratio index (>1.01) were risk factors for survival and BCLC stage A was a good prognostic factor for OS in group 1 treated by TACE. Conclusions: Serglycin in peripheral blood cells was increased significantly in HBV infected HCC patients. Average fluorescence intensity of seglycin in peripheral neutrophils was found to be an independent predictor of prognosis for HCC patients, not limited by infective complications and was superior to other inflammation prognostic factors. Based on the data from the current study, we propose, testing of serglycin levels is a simple and feasible way to predict prognosis for HCC patients with TACE.
Please use this identifier to cite or link to this item: